Navigation Links
Possible Reason for Rimonabant's Side Effects Discovered
Date:3/12/2008

Weight-loss drug not approved in U.S. may block brain receptor among some users

WEDNESDAY, March 12 (HealthDay News) -- The weight-loss drug rimonabant has been associated with troubling psychiatric side effects, and now researchers think they have discovered why.

A receptor in the brain called TRPV1, which is central to learning and memory, may be blocked by large doses of rimonabant (Acomplia), resulting in depression, anxiety and suicidal thoughts among some people taking the drug, a new study shows.

"We think that changes in the strength of connections between neurons in the brain underlie all kinds of important changes in the brain like learning, the development of the nervous system and many other adaptations to the environment, such as responses to pain and responses to drugs," said lead researcher Julie Kauer, an associate professor of molecular pharmacology, physiology and biotechnology at Brown University in Rhode Island.

The report was published in the March 13 issue of Neuron.

In experiments with rat brains, Kauer's group found that TRPV1 controls a brain mechanism called long-term depression, which is thought to be a key component in memory. The team thinks this finding may relate to the psychiatric side effects that have been seen with Acomplia.

"We found that rimonabant blocked TRPV1, and also another receptor CB1. It's possible that when the patient takes the drug, and the dose range is correct, it may not affect TRPV1 at all," Kauer said. "However, in some patients, Acomplia could be hitting TRPV1 and may well have an effect on activating this receptor," she said.

Acomplia is used widely outside the United States. To date, the U.S. Food and Drug Administration has not approved Acomplia because of its psychiatric side effects.

In addition, the researchers found that a new class of painkillers may interfere with learning and memory, because they also block TRPV1.

"They're all these other drugs that are supposed to target peripheral pain, and there hasn't been a lot of attention paid to whether they cross into the brain, Kauer said. That's something that needs to be paid attention to, because now we're showing that these drugs are depressing brain synapses," she said.

One expert thinks the study may have identified the reason for mood disorders associated with Acomplia, but it doesn't speak to the issue of whether the drug's benefits outweigh the risks.

"This is an interesting study which is important in potential mechanisms that could explain the higher incidence of mood disorders associated with rimonabant use," said Dr. Raj Padwal, an assistant professor of general internal medicine at the University of Alberta in Canada.

However, Padwal, who has studied the risks and benefits of weight-loss drugs, thinks there are still questions about whether the drug causes mood disorders or not.

"If it does cause mood disorders, what is the increased risk? Does the increased risk of mood disorders then outweigh the potential benefits of the drug such that the drug should not be approved?" Padwal asked.

This study is nice in elucidating potential mechanisms but not really helpful in teasing out whether the drug should be approved, Padwal said. "For approval, I'm sure the FDA is looking for post-marketing surveillance data from Europe and other countries of the world in which the drug is being used," he added.

More information

For more on obesity, visit the National Institutes of Health.



SOURCES: Julie Kauer, Ph.D., associate professor, molecular pharmacology, physiology and biotechnology, Brown University, Providence, R.I.; Raj Padwal, M.D., assistant professor, general internal medicine, University of Alberta, Edmonton, Canada; March 13, 2008, Neuron


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Teamsters Warn of Possible Work Stoppages, Service Disruptions at AmerisourceBergen
2. Researchers find possible target to treat deadly bloodstream infections
3. Brain stress system presents possible treatment
4. Good Outcomes Possible for Older Lung Transplant Patients
5. Yale study offers insight into possible cause of lymphoma
6. Vaccine for stomach flu may be possible, UNC research shows
7. Childrens Hospital scientists identify possible target for prevention and treatment of pneumonia
8. Model found to determine cause, possible treatment of nerve tumors
9. Contact lenses with circuits, lights a possible platform for superhuman vision
10. Protein a possible key to allergy and asthma control
11. Possible Cure for Rare Lymphoma Reported
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Possible Reason for Rimonabant's Side Effects Discovered 
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... East Los ... dental extractions. Currently, patients can visit Dr. Assili to receive any dental extraction treatment ... offer, and it expires June 30, 2016. With the lower price, patients can more ...
(Date:5/2/2016)... ... May 02, 2016 , ... Zitter Health Insights , ... Satisfaction Award that will recognize specialty pharmacies for their achievements in customer satisfaction. ... Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results will be published in ...
(Date:5/2/2016)... Fla. (PRWEB) , ... May ... ... medical researchers report that many commonly used prescription medications, including anxiolytics, painkillers, ... To mitigate these risks, Novus Medical Detox Center —a leading Florida-based ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a new company developing ... and improve the rapid diagnosis, triage and admission of patients leveraging IBM Watson’s ... mobile experience for the first time at GENBAND’s Perspectives16 conference. , TeleMedCo ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Atlantic Information ... CMS’s Medicare Part B Payment Model Could Transform the Pharma Landscape .” CMS recently ... on reducing its spend on provider-administered drugs while preserving care provided to beneficiaries. The ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
Breaking Medicine Technology: